Cognetivity Neurosciences Ltd. announced that it has reached a commercial agreement with American Center for Psychiatry and Neurology (ACPN) in the United Arab Emirates (UAE). ACPN is a specialist medical facility with branches in the cities of Abu Dhabi, Dubai and Al Ain. Dedicated to the provision of high-quality neurological, psychiatric, psychological and rehabilitation services, ACPN is the leading provider of its kind in the UAE.

The center is also an accredited research body, having been involved in numerous high-profile published studies in the region, and has ongoing research collaborations with organizations such as the Harvard Medical School Center for Global Health Delivery, Biogen, Novartis and IQVIA. The commercial agreement between Cognetivity and ACPN will see Cognetivity's CognICATM brain health screening platform deployed as a screening and monitoring tool at ACPN's newly established memory clinic. In the future, the deployment may be expanded to cover additional ACPN services and to support research studies in the Alzheimer's disease space, among others.

CognICATM is approved for clinical use in the USA and EU and is already commercially deployed in the UAE, North America and in the UK's National Health Service (NHS). The technology uses artificial intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring.